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Abstract 
Review on t(11;14)(p13;q32), with data on clinics, 
and the genes involved. 
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Clinics and pathology 
Disease 
Mature B-cell non-Hodgkin Lymphomas (NHL). 
Nine cases available so far, from a unique study (Hu 
et al., 2010). 
Phenotype/cell stem origin 
In a study of 114 cases of mature B-cell NHLs, the 
t(11;14)(p13;q32) IGH/CD44 was found in:  
- 4 cases (8%) of gastric lymphoma; mucosa-
associated lymphoid lymphoma (MALT): 1 (25%); 
composite DLBCL with residual MALT lymphoma: 
2 (33%); diffuse large B-cell lymphoma (DLBCL) 
germinal center B-cell-like (GCB)-type: 1 (4%); 
- 2 cases (25%) of non-gastric extranodal lymphoma: 
DLBCL GCB-type: 2 (67%); 
- 2 cases (7%) of follicular lymphoma (FL), one of 
which also harboring a t(14;18)(q32;q21) 
IGH/BCL2; 
- 1 cases (4%) of nodal DLBCL GCB-type. 





20 exons spanning 60 kb. The first five and the last 
five exons are constant; while the ten exons located 
between, are subject to alternative splicing, resulting 
in the generation of CD44 variants. 
Protein 
CD44 is composed of extracellular, transmembrane, 
and cytoplasmic domains. CD44 is a membrane 
receptor which plays a role in cell adhesion (cell-cell 
and cell-extracellular matrix interactions), cell 
traffic, presentation of chemokines and growth 
factors, signals transmission. High levels of 
expression of CD44 have been observed in a high 
number of cancer types, including non-Hodgkin 
Lymphomas (Sen and Yip 2010). 
IGH 
Location 14q32.33 




5' IGH-3' CD44. 
The translocation juxtaposes the IGHSμ enhancer to 
the 5' regulatory region of CD44 in a tail-to-head 
orientation. Various breakpoints: breakpoints were 
spread within small regions of IGHSμ and small 
regions between CD44 exon 1 and 2. 










CD44 starting from the ATG at nucleotide 254 with 
a strong Kozak sequence. 
Oncogenesis 
The ectopic expression of CD44 resulted in increase 
in cell growth and clonogenicity. To be noted is that 
the t(11;14)(p13;q32) was detected in 4 patients with 
advanced stages of disease. 
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